Current Report Filing (8-k)
November 13 2019 - 4:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 13, 2019
DECIPHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38219
|
|
30-1003521
|
(State or other jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
200 Smith Street
Waltham, MA
|
|
02451
|
(Address of registrants principal executive office)
|
|
(Zip code)
|
(781) 209-6400
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
|
|
|
|
Title of each class
|
|
Trading
Symbol
|
|
Name of exchange
on which registered
|
Common Stock, $0.01 Par Value
|
|
DCPH
|
|
The Nasdaq Global Select Market
|
Item 7.01.
|
Regulation FD Disclosure.
|
On November 13, 2019, Deciphera Pharmaceuticals, Inc., or the Company, issued a press release announcing preliminary data from its ongoing
Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, including data in patients with diffuse-type tenosynovial giant cell tumor. The data were presented on November 13, 2019 (November 14, 2019 local
time) in a poster session at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting being held November 13-16, 2019 in Tokyo, Japan. A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K, and a copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The furnishing of the attached press release and presentation is not an admission as to the materiality of any information therein. The
information contained in the press release and the presentation is summary information that is intended to be considered in the context of more complete information included in the Companys filings with the U.S. Securities and Exchange
Commission, or the SEC, and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report,
although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important
information about forward looking statements, see the Cautionary Note Regarding Forward-Looking Statements section of the press release in Exhibit 99.1 attached hereto.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1
and Exhibit 99.2 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 and in the presentation attached as Exhibit 99.2 to this Current Report shall not be incorporated by reference
into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date November 13, 2019
|
|
|
|
DECIPHERA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Steven L. Hoerter
|
|
|
|
|
|
|
Steven L. Hoerter
|
|
|
|
|
|
|
President and Chief Executive Officer
|
3
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Sep 2023 to Sep 2024